...
nrix-img

Nurix Therapeutics Inc, Common Stock

NRIX

NMQ

$20.24

-$0.94

(-4.44%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.47B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.34M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.20
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.65 L
$29.56 H
$20.24

About Nurix Therapeutics Inc, Common Stock

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNRIXSectorS&P500
1-Week Return-5.02%-2.06%-0.55%
1-Month Return-7.11%-1.92%2.72%
3-Month Return-18.19%-10.4%7.66%
6-Month Return9.76%-4.6%10.15%
1-Year Return124.89%4.06%27.53%
3-Year Return-27.71%1.94%32.31%
5-Year Return6.47%36.48%89.2%

Financials

Nov '19Nov '20Nov '21Nov '22Nov '235YR TREND
Total Revenue31.11M17.82M29.75M38.63M76.99M[{"date":"2019-11-30","value":40.42,"profit":true},{"date":"2020-11-30","value":23.15,"profit":true},{"date":"2021-11-30","value":38.64,"profit":true},{"date":"2022-11-30","value":50.17,"profit":true},{"date":"2023-11-30","value":100,"profit":true}]
Cost of Revenue45.02M66.49M6.08M10.81M189.15M[{"date":"2019-11-30","value":23.8,"profit":true},{"date":"2020-11-30","value":35.15,"profit":true},{"date":"2021-11-30","value":3.22,"profit":true},{"date":"2022-11-30","value":5.71,"profit":true},{"date":"2023-11-30","value":100,"profit":true}]
Gross Profit(13.91M)17.82M29.75M38.63M(112.16M)[{"date":"2019-11-30","value":-36.01,"profit":false},{"date":"2020-11-30","value":46.13,"profit":true},{"date":"2021-11-30","value":77.02,"profit":true},{"date":"2022-11-30","value":100,"profit":true},{"date":"2023-11-30","value":-290.37,"profit":false}]
Gross Margin(44.71%)100.00%100.00%100.00%(145.69%)[{"date":"2019-11-30","value":-44.71,"profit":false},{"date":"2020-11-30","value":100,"profit":true},{"date":"2021-11-30","value":100,"profit":true},{"date":"2022-11-30","value":100,"profit":true},{"date":"2023-11-30","value":-145.69,"profit":false}]
Operating Expenses53.35M82.80M147.64M222.49M232.05M[{"date":"2019-11-30","value":22.99,"profit":true},{"date":"2020-11-30","value":35.68,"profit":true},{"date":"2021-11-30","value":63.62,"profit":true},{"date":"2022-11-30","value":95.88,"profit":true},{"date":"2023-11-30","value":100,"profit":true}]
Operating Income(22.24M)(64.98M)(117.89M)(183.87M)(155.06M)[{"date":"2019-11-30","value":-2223600000,"profit":false},{"date":"2020-11-30","value":-6498300000,"profit":false},{"date":"2021-11-30","value":-11788600000,"profit":false},{"date":"2022-11-30","value":-18386700000,"profit":false},{"date":"2023-11-30","value":-15506300000,"profit":false}]
Total Non-Operating Income/Expense1.55M2.41M1.65M7.01M22.23M[{"date":"2019-11-30","value":6.98,"profit":true},{"date":"2020-11-30","value":10.85,"profit":true},{"date":"2021-11-30","value":7.4,"profit":true},{"date":"2022-11-30","value":31.55,"profit":true},{"date":"2023-11-30","value":100,"profit":true}]
Pre-Tax Income(21.46M)(63.78M)(117.06M)(180.36M)(143.95M)[{"date":"2019-11-30","value":-2146000000,"profit":false},{"date":"2020-11-30","value":-6377700000,"profit":false},{"date":"2021-11-30","value":-11706300000,"profit":false},{"date":"2022-11-30","value":-18036000000,"profit":false},{"date":"2023-11-30","value":-14394800000,"profit":false}]
Income Taxes239.00K(20.54M)131.00K(14.31M)13.49M[{"date":"2019-11-30","value":1.77,"profit":true},{"date":"2020-11-30","value":-152.27,"profit":false},{"date":"2021-11-30","value":0.97,"profit":true},{"date":"2022-11-30","value":-106.15,"profit":false},{"date":"2023-11-30","value":100,"profit":true}]
Income After Taxes(21.70M)(43.24M)(117.19M)(166.04M)(157.43M)[{"date":"2019-11-30","value":-2169900000,"profit":false},{"date":"2020-11-30","value":-4324200000,"profit":false},{"date":"2021-11-30","value":-11719400000,"profit":false},{"date":"2022-11-30","value":-16604500000,"profit":false},{"date":"2023-11-30","value":-15743410500,"profit":false}]
Income From Continuous Operations(21.70M)(43.24M)(117.19M)(180.36M)(143.95M)[{"date":"2019-11-30","value":-2169900000,"profit":false},{"date":"2020-11-30","value":-4324200000,"profit":false},{"date":"2021-11-30","value":-11719400000,"profit":false},{"date":"2022-11-30","value":-18036000000,"profit":false},{"date":"2023-11-30","value":-14394800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-11-30","value":"-","profit":true},{"date":"2020-11-30","value":"-","profit":true},{"date":"2021-11-30","value":"-","profit":true},{"date":"2022-11-30","value":"-","profit":true},{"date":"2023-11-30","value":"-","profit":true}]
Net Income(21.70M)(43.24M)(117.19M)(166.04M)(143.95M)[{"date":"2019-11-30","value":-2169900000,"profit":false},{"date":"2020-11-30","value":-4324200000,"profit":false},{"date":"2021-11-30","value":-11719400000,"profit":false},{"date":"2022-11-30","value":-16604500000,"profit":false},{"date":"2023-11-30","value":-14394800000,"profit":false}]
EPS (Diluted)-(4.10)(2.73)(3.73)(2.65)[{"date":"2019-11-30","value":"-","profit":true},{"date":"2020-11-30","value":-410,"profit":false},{"date":"2021-11-30","value":-273,"profit":false},{"date":"2022-11-30","value":-373,"profit":false},{"date":"2023-11-30","value":-265,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NRIX
Cash Ratio 5.19
Current Ratio 5.28
Quick Ratio 5.29

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NRIX
ROA (LTM) -29.46%
ROE (LTM) -57.96%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NRIX
Debt Ratio Lower is generally better. Negative is bad. 0.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.73

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NRIX
Trailing PE NM
Forward PE NM
P/S (TTM) 26.13
P/B 3.91
Price/FCF NM
EV/R 18.67
EV/Ebitda NM

FAQs

What is Nurix Therapeutics Inc share price today?

Nurix Therapeutics Inc (NRIX) share price today is $20.24

Can Indians buy Nurix Therapeutics Inc shares?

Yes, Indians can buy shares of Nurix Therapeutics Inc (NRIX) on Vested. To buy Nurix Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NRIX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Nurix Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Nurix Therapeutics Inc (NRIX) via the Vested app. You can start investing in Nurix Therapeutics Inc (NRIX) with a minimum investment of $1.

How to invest in Nurix Therapeutics Inc shares from India?

You can invest in shares of Nurix Therapeutics Inc (NRIX) via Vested in three simple steps:

  • Click on Sign Up or Invest in NRIX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Nurix Therapeutics Inc shares
What is Nurix Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Nurix Therapeutics Inc (NRIX) is $29.56. The 52-week low price of Nurix Therapeutics Inc (NRIX) is $7.65.

What is Nurix Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Nurix Therapeutics Inc (NRIX) is

What is Nurix Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Nurix Therapeutics Inc (NRIX) is 3.91

What is Nurix Therapeutics Inc dividend yield?

The dividend yield of Nurix Therapeutics Inc (NRIX) is 0.00%

What is the Market Cap of Nurix Therapeutics Inc?

The market capitalization of Nurix Therapeutics Inc (NRIX) is $1.47B

What is Nurix Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Nurix Therapeutics Inc is NRIX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top